GMED swine flu news just out!
GenoMed Offers Possible Alternative Treatment for Swine Flu
FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
Tel. 314.983.9933
dwmoskowitz@genomed.com
ST. LOUIS—April 27, 2009—GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced today that its concept of a general viral antidote may be especially useful for the current swine flu epidemic.
In Mexico, young, healthy people are dying from swine flu, as in the case of the 1918 epidemic. The press is finally reporting that this may be due to "cytokine storm." Healthy people mount an exaggerated immune response to a new virus, so that it's their own overly healthy immune system that kills them, rather than the virus itself. This is a new concept of viral diseases that GenoMed began promoting during the SARS epidemic six years ago.
Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "Swine flu has two known treatments already, Tamiflu and Relenza. But for communities without access to these expensive medications, GenoMed offers the possibility that a cheaper and much more available class of medications, the ARBs (angiotensin II receptor blockers) or ACE inhibitors, which are present in every drug store on earth, may also work."
Dr. Moskowitz continued, "Anybody interested in our free clinical trial for swine flu is welcome to contact me at dwmoskowitz@genomed.com."
About GenoMed
GenoMed is a Next Generation Disease Management (DM) company that aims to deliver the best patient outcomes at the lowest possible cost. Being so active in clinically oriented research is what makes GenoMed a "Next Generation DM(tm)" company.
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, especially whether our approach will actually work for swine flu, but also including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
